About Probable RNA polymerase II nuclear localization protein SLC7A6OS
Probable RNA polymerase II nuclear localization protein SLC7A6OS (SLC7A6OS) is a protein
from Homo sapiens identified by UniProt accession
Q96CW6, 309 residues long.
MolForge cross-references it against 0 known binders and
53 disease associations.
Target properties
| Protein name | Probable RNA polymerase II nuclear localization protein SLC7A6OS |
| UniProt accession | Q96CW6 |
| Gene | SLC7A6OS |
| Organism | Homo sapiens |
| Length | 309 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (53)
Diseases linked to this target (Open Targets).
- epilepsy, progressive myoclonic, 12 · score 0.46
- Generalized myoclonic seizure · score 0.27
- creatinine measurement · score 0.25
- diastolic blood pressure · score 0.24
- serum non-albumin protein measurement · score 0.23
- glomerular filtration rate · score 0.20
- metabolite measurement · score 0.15
- blood metabolite measurement · score 0.14
- body mass index · score 0.13
- serum metabolite measurement · score 0.11
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q96CW6-F1 | alphafold | PREDICTED | 65.46 | — |
Amino-acid sequence (309 residues)
MEAARTAVLR VKRKRSAEPA EALVLACKRL RSDAVESAAQ KTSEGLERAA ENNVFHLVAT VCSQEEPVQP LLREVLRPSR DSQQRVRRNL RASAREVRQE GRYRVLSSRR SLGTTSSGQE SEYTPGNPEA AGNSGFQLLD LVHEEGEPEA ASAGSCKTSD PDVILCNSVE LIRERLTVSE DGPGVRRQEE QKHDDYVYDI YYLETATPGW IENILSVQPY SQEWELVNDD QEPEDIYDDE DDENSENNWR NEYPEEESSD GDEDSRGSAD YNSLSEEERG SSRQRMWSKY PLDVQKEFGY DSPHDLDSD
Explore Probable RNA polymerase II nuclear localization protein SLC7A6OS with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets